GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2

May 31, 2024 11:16 PM AEST | By Cision

GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2 — Image source: Kalkine Media

Recent News

247connect Makes Remote Desktop Access Simple and Affordable!

Monroe Capital, SMBC and MA Financial Launch US$1.7 Billion Middle Mar...

Kasada’s Q1 2025 Threat Intel Report Uncovers ALTSRUS “Reverse Robin H...

Asana Launches Smart Workflow Gallery, a Blueprint for Effective Human...

SHANGHAI, May 31, 2024 /PRNewswire/ -- Shanghai Grit Biotechnology Co., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) announced the establishment of a formal strategic partnership to leverage both parties' R&D capabilities in innovative T-cell therapy. The objective is to jointly develop a globally standardized IL-2 for solid tumor patients receiving T-cell therapy, aiming to localize the global standard IL-2 with accessible prices for Chinese patients.

The focus of the collaboration will be on expanding the indications of Quanqi (125SER) Interleukin-2 (I) products for solid tumors. Quanqi (125SER), as a domestically marketed human Interleukin-2, is primarily used in the treatment of solid tumors such as renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, colorectal cancer, lymphoma, and lung cancer, etc. Both parties will collaborate to develop a domestically produced substitute to the globally recognized immune-regulating cytokine IL-2 in T-cell therapy, addressing the significant unmet medical needs for Chinese cancer patients.

Grit is a clinical stage cell therapy company leading the tumor infiltrating lymphocytes (TILs) therapy development in China. Grit's non-gene-engineered TIL program GT101 is in Phase 2 (pivotal) trial -- it is the fastest TIL pipeline in China and plans for BLA filing in 2025. Quangang Pharmaceutical is a leading domestic biopharmaceutical company dedicated to the research and development of genetic medicines, boasting GMP facilities and a specialized biotechnology research institute. Both parties have rich technical expertise and product development experience, along with a strong reputation and influence in the biopharmaceutical field in China.

Through this collaboration, GRIT will leverage its extensive experience in T cell therapy to expedite the advancement and commercialization of cell therapy products, providing a broader range of options and instilling hope for a greater number of solid tumor patients in the Chinese market. Both parties affirm that through their joint efforts, there is anticipation for a broader spectrum of Chinese patients to soon gain access to advanced and efficacious T-cell treatment options with the affordable local IL-2 product.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.